gonadiene-3-one (gestodene), a new synthetic progestogen displaced 3H-oestradiol (3H-E2) from both ERc and ERn in malignant tissue but not in normal breast, or these receptors from endometrial tissue. In competition studies gestodehe was 3 times more effective in displacing 3H-E2 from ERC and ERn in malignant breast tissue than the natural ligand. Quantitation of ER by gestodene were ERr, 12-1134 fmol gestodene bound mg-soluble protein (Kd 1 x 10-9-8.1 x 10-9 mol l-1); ER., 17-531 fmol gestodene bound mg ' soluble protein (Kd 1.6 x O1-9.1 x 10 8moll-'). L-13-ethyl-17a-ethinyl, 17,B-hydroxy-gonen-3-one (levonorgestrel) showed no binding to ER in malignant breast, normal breast or endometrial tissue. In circulation both gestodene and levonorgestrel displaced E2 from sex hormone binding globulin more than any of the androgens tested. These results suggest that gestodene is a progestogen with oestrogenic and/or antioestrogenic properties and provide strong evidence for differences in ER from malignant and normal breast tissue.
Oestrogen receptor (ER) in human carcinoma of the breast is the most widely studied steroid receptor. ER has been extensively purified and characterised (Jensen et al., 1982) and perhaps together with the glucocorticoid receptor more is known about its physicochemical forms and characteristics than any other receptor (McGuire et al., 1978; Grody et al., 1982) . However, many points of contention still remain (King & Green, 1984; Welshons et al., 1984; Szego & Pietra, 1985) .
Recently, Jasper et al. (1985) reported different physicochemical forms of ER in rat uterus and pituitary gland based on the hypothesis of a monomer-dimer relationship, and Brown et al. (1984) found that the E2 dependent pS2 gene was expressed in the MCF-7 cell line and malignant breast samples but not in normal breast or ER negative cell lines. Similarly, there have been many reports on multiple receptor forms in tissues from animals of different ages and endocrine status (Jasper et al., 1985) , on the sedimentation behaviour of molybdate stabilised, non-activated ER, on ER bound to E2 or to antioestrogens and salt or heat-activated receptor (Katzenellenbogen et al., 1978 (Katzenellenbogen et al., , 1981 McGuire et al., 1978; Grody et al., 1982 and Keen et al., 1984) . To date, however, in no organ in any species have differences in binding of a particular steroid metabolite or analogue by ER been reported in a malignant tissue as compared to the normal tissue of the same organ.
Here we report the significant binding of a synthetic progestogen to ER in human malignant breast tissue and its total lack of binding to ER in normal breast tissue or to ER in endometrium. This is all the more surpising because the 'down regulation' of ER by progestogens has been reported (Katzenellenbogen, 1980) activity 5.30 TBq mmol-1), 3H-17,B-hydroxyandrost-4-en-3-one (testosterone) (specific activity 3.89 TBq mmol 1), 3H-5a-androstan-3a(3,B)-diols (specific activities 1.52 TBq mmol-1 each), 3H-1 #,17,21-trihydroxy pregn-4-ene-3,20-dione (cortisol) (specific activity 3.0 TBq mmol-1) and 3H-pregn-4-ene-3,20-dione (progesterone) (specific activity 3.66 TBq mmol-') were purchased from Amersham International, UK. Radioinert steroids were obtained from Sigma Chemical Co. UK. In all instances the purity of the steroids used was greater than 99.9% as determined by thin layer chromatography before use. Sephadex G-25, Sephadex LH-20 and Sepharose 6B were obtained from Pharmacia (GB) Ltd. Cibacron Blue 3GA-Sepharose 6B was prepared as described by Heyns and De Moor (1974) . Radioactivity was determined in a Packard Tri-Carb liquid scintillation counter with an efficiency of 40% using 'Optiphase Safe' (LKB/Fisons) as scintillant. Data were analysed by Scatchard plots (Scatchard, 1949) , with resolution of curvilinear plots by the method of Chamness and McGuire (1975) .
Breast tissue was obtained at operation; malignant breast samples were confirmed histologically and normal breast samples were obtained either from surrounding tissue (samples 1-6, Table I ) which was histologically confirmed as normal or from operative breast reduction (samples 7-9, Table II ) and were stored in liquid nitrogen until assayed.
Estimation of ER Cytosol and nucleosol fractions were prepared as previously described (Greenway et al., 1981; Iqbal et al., 1983) and the original tissue weight:volume buffer was 1:20 in the incubates. Tissue samples were manipulated below 4°C and were homogenised in TED buffer (10mMTris, 1.5mMEDTA and 1.5mM dithiothreitol, pH 7.4) using an Ultra-Turrax homogeniser before centrifugAtion at 160,000g for 1h, the resulting supernatant was used as cytosol.
The remaining pellet was washed with TES buffer (10 mm Tris, 1 mm EDTA and 250 mm sucrose, pH 7.4), centrifuged at 800g for 10min and the supernatant discarded. The pellet was then homogenised in TSMK buffer (10mmTris, 250mM sucrose, 5mM MgCl2 and 25 mm KCI, pH 7.5), centrifuged at 800g for 10 min and the supernatant discarded. The pellet was washed twice with TSMK bufffer and finally suspended in TKED buffer (TED buffer containing 0.5 M KCl). The suspension was kept at 4°C for 1 h to extract nuclear receptor and then centrifuged at 15,000g for 30 min, the supernatant being retained as nucleosol.
ER was measured using the two-tier column microassay employing Cibacron Blue 3GA-Sepharose 6B for the affinity immobilisation of the receptor and the steroid bound to it (Iqbal et al., 1985) . Aliquots (0.4ml) of cytosol or nucleosol were incubated with a constant amount (6,000c.p.m.) of 3H-E2 and increasing amounts of radioinert E2 (0-18.4 pmol). Cytosols were assayed after 2 h of incubation and nucleosols were assayed after 18h of incubation. In the assay 0.1 ml aliquots of these incubates were applied to the microassay columns in duplicate. The column comprises a glass microcolumn fitted with a cellulose acetate plug, the upper layer consisting of 0.5ml of Cibacron Blue 3GA-Sepharose 6B and the lower layer 1 ml of Sephadex LH-20. The columns were eluted with either 2.7 ml cytosol assay buffer (10 mm Tris, 1.5 mm EDTA, pH 7.4) for the cytosolic ER or 2.7 ml nucleosol assay buffer (10 mm Tris, 250mM sucrose, 5mM MgCl2, 25mmKCL, pH7.4). After cutting the columns at the interface of the two gels, the radioactivity in the Blue gel fraction was determined. Eleven samples of malignant breast, 9 of normal breast and 3 of endometrium were assayed.
Competition studies for ER In samples of normal breast (n = 9), malignant breast (n=ll) and endometrium (n=3), cytosolic and nucleosolic preparations were made as above. Aliquots (0.4ml) of these were incubated (cytosols for 2 h and nucleosols for 18 h) with a constant amount of 3H-E2 (6,000 c.p.m.) and varying amounts (0-16 pmol) of either gestodene or levonorgestrel, and also using varying amounts (0-18.4pmol) of radioinert E2. Displacement of the 3H-E2 was studied with the microassay. CaC12, pH 7.5) and was used throughout. Aliquots (0.4 ml) of the above dilution were incubated as described for the two-tier column SHBG assay (Iqbal & Johnson, 1977) with constant amounts (25,000 c.p.m.) of either 3H-DHT, 3H-testosterone, 3H-E2, 3H-5a-androstane-3a(or 3ft, 17#-diol and varying amounts (0-180 pmol) of their respective radioinert moieties. In a parallel series of experiments displacement of the above tritiated steroids was carried out with 0-165pmol amounts of either radioinert gestodene or radioinert levonorgestrel.
(ii) Displacement from corticosteroid binding globulin (CBG) The two-tier columns were prepared as above except that the Sephadex LH-20 gel in the lower tier was replaced by 1 ml of Sephadex G-25. The rest of the experimental conditions were as in (i) above. Displacement of 3H-progesterone and 3H-cortisol was studied by using varying concentrations (0-180 pmol) of their respective radioinert ligands and in a parallel series of experiments .displacement of 3H-progesterone and 3H-cortisol was studied by using varying amounts of radioinert gestodene or levonorgestrel (0-165 pmol).
Results
Of the 11 samples of the carcinoma of the breast assayed 9 were ER, positive (1-6, 8, 10 and 11, Figure 1) . In normal breast obtained from the corresponding carcinoma of the breast tissue (1-6, Table I ) ERC was positive in samples 1, 3-6 (Table II) ; ERC in samples 7-9 was also positive (Table II, Figure 2 ). ERn in normal breast was detected only in two samples (3 and 8, Table II ).
All three samples of endometrium were ERC and ER, positive, ERc: 191, 495, 326fmol E2 bound mg-1 soluble protein and ERn: 34, 176 and 59 fmol mg-1 soluble protein respectively (Kd 7.1, 6.8 and 7.2x 10-9molI-1 for ERc, and for ERn 3.0, 3.5 and 4.6 x 10-9 mol 1-I respectively).
Competition studies showed that gestodene displaced 3H-E2 from ER, and ER, in malignant (Figures 1 and 2 +0.9987 (P<0.01) .
Fifty percent displacement of 3H-DHT, 3H-testosterone, 3H-E2, 3H-5a-androstane-3a, 17f-diol and 3H-5a-androstane-3p, 17f,-diol from SHBG in circulation by gestodene were achieved by concentrations 560%, 235%, 65%, 75% and 80% of their natural ligand respectively. Similar studies with levonorgestrel showed that gestodene was -20% more effective in these displacements than was the former analogue. No displacement of 3H-progesterone or 3H-cortisol from CBG in circulation was caused by either gestodene or levonorgestrel.
a Discussion
Gestodene is structurally closely related to levonorgestrel and its optical isomer d-norgestrel. The 0.10 latter compound has been shown to displace sexsteroids from SHBG in circulation (Victor et al., m 1u 1976). While it is surprising that a progestogen hydroxy-gonen-3-one (levonorgestrel).
D
In relation to the binding of gestodene to ER in malignant breast tissue, the findings are much more unexpected and have far reaching implications. This study demonstrates for the first time that a steroidal compound exhibits binding to ER from malignant breast but not to that from normal breast. This indicates a structural difference between the two receptors. In competition studies the results show that gestodene can displace 3H-E2 by about 3-fold as compared to the natural ligand, however, when ER from malignant breast tissue is measured using this synthetic steroid there is little difference in the total steroid bound or in the dissociation constant suggesting that gestodene prevents binding of E2 not only by competing for the binding site on ER but perhaps also by interfering with the formation of E2-ER complex. 
